Abstract
In the peritoneal plasmacytomagenesis (PCTG) model system, plasmacytomas (PCTs) are induced when different kinds of metabolically inert substances (paraffin oils, silicones, polycarbonate solid discs) are introduced into the peritoneal cavities of genetically susceptible BALB/cAn mice. The PCTs develop morphologically in the chronic inflammatory tissue that forms in peritoneal connective tissues in response to these agents. The most extensively studied agent is pristane (2,6,10,14-tetramethylpentadecane)1,2. This induction system has been useful in identifying steps and biological determinants in plasma cell neoplasia. Important features of pristane PCTG in the mouse are: 1) the remarkable dependence on the BALB/cAn genotype and, specifically, the chromosome-4 PCT susceptibility genes Pctr 1 and Pctr23,4; 2) the consistent (>95%) appearance of chromosomal translocations t(6;15)or t(12;15) that are associated with rearrangement of Immunoglobulin (Ig) genes and c-myc and result in the deregulation of c-myc transcription5,6; 3) the influence of natural antigenic stimulation [Specific Pathogen Free BALB/cAnPt mice that have a very restricted exposure to environmental antigens are resistant to PCT induction by pristane7]; 4) the dependence upon the special vascular and immunological properties of the peritoneal space8; and 5) the dependence for growth and progression on the reactive chronic inflammatory microenvironments and cytokines, e.g., IL-69–11.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Refferences
Anderson, P. N. & Potter, M. Nature222, 994–995 (1969).
Porter, M. & Wax, J. S. J. Natl. Cancer Inst.71, 391–395 (1983).
Mock, B. A., Krall, M. M. & Dosik, J. K. Proc. Natl. Acad. Sci. USA90, 9499–9503 (1993).
Potter, M., Mushinski, E. B., Wax, J. S., Hartley, J. & Mock, B. A. Cancer Res.54, 969–975 (1994).
Mushinski, J. F. in Cellular Oncogene Activation(ed Klein, G.) 181–222 ( Marcel Dekker, Inc. New York, 1988).
Cory, S.Adv. Cancer Res.47, 189–211 (1986).
Byrd, L. G., McDonald, A. H., Gold, L. G. & Potter, M. J. Immunol.147, 3632–3637 (1991).
Anderson, A. O., Wax, J. S. & Potter, M. Curr. Top. Microbiol. Immunol.122, 242–253 (1985).
Hinson, R. M., Williams, J. A. & Shacter, E. Proc. Natl Acad. Sci. USA93, 4885–4890 (1996).
Nordan, R. P. & Potter, M. Science233, 566–569 (1986).
Lattanzio, G, Libert, C, Aquilina, M., et al. Am.J. Pathol.151, 689–696 (1997).
Muller, J. R, Jones, G. M., Janz, S. & Potter, M. Blood 89, 291–296 (1997).
Potter, M., Wax, J. S., Anderson, A. O. & Nordan, R. P. J. Exp. Med.161, 996–1012 (1985).
Potter, M., Wax, J. & Jones, G. M. Blood90, 260–269 (1997).
Merwin, R. M. & Redmon, L. W. J. Natl. Cancer Inst.31, 990–1007 (1963).
Abramson, S. B. & Weissmann, G.Arthritis Rheum.32, 1–9 (1989).
Levy, G. N. FASEB J. 11, 234–247 (1997).
Loll, P. J. in New targets in inflammation. Inhibitors of COX-2 or adhesion molecules(eds Bazan, N., Botting, J. & Vane, J.) 13–21 (Kluwer Academic Publishers, Dordrecht, 199
Picot, D., Loll, P. J. & Garavito, R. M. Nature367, 243–249 (1994).
Lehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M. & Kliewer, S. A. J. Biol. Chem.272, 3406–3410 (1997).
Arkins, S., Rebeiz, N., Biragyn, A., Reese, D. L. & Kelley, K. W. Endocrinology133, 2334–2343 (1993).
McDonald, A. H. & Degrassi, A. Cell.Immunol146, 157–170 (1993).
Shacter, E., Beecham, E. J., Covey, J. M., Kohn, K. W. & Potter, M. Carcinogenesis9, 2297–2304 (1988).
Schraufstatter, I., Hyslop, P. A., Jackson, J. H. & Cochrane, C. G. J.Clin.Invest.82, 1040–1050 (1988).
Umeki, S. BiochemPharmacol.40, 559–564 (1990).
Smith, R. J. & Iden, S. S. BiochemPharmacol29, 2389–2395 (1980).
Oyanagui, Y. Biochem.Pharmacol.25, 1473–1480 (1976).
Aruoma, O. I. & Halliwell, B.Xenobiotica 18, 459–470 (1988).
Marnett, L. J. Environ. Health Perspect.88, 5–12 (1990).
Schreck, R. & Baeuerle, P. A. Trends Cell Biol.1, 39–42 (1991).
Di Gianni, P., Minnucci, F. S., Alves Rosa, M. F., Vulcano, M. & Isturiz, M. A. ScandJ. Immunol43, 413–420 (1996).
Marnett, L. J. Cancer Res.52, 5575–5589 (1992).
Hanif, R., Pittas, A., Feng, Y., et al. BiochemPharmacol.52, 237–245 (1996).
Chan, T. A., Morin, P. J., Vogelstein, B. & Kinzler, K. W. Proc. Natl. Acad. Sci. U. S. A.95, 681–686 (1998).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Potter, M. (1999). Indomethacin Inhibition of Pristane Plasmacytomagenesis in Genetically Susceptible Inbred Mice. In: Honn, K.V., Marnett, L.J., Nigam, S., Dennis, E.A. (eds) Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Radiation Injury, 4. Advances in Experimental Medicine and Biology, vol 469. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4793-8_23
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4793-8_23
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7171-7
Online ISBN: 978-1-4615-4793-8
eBook Packages: Springer Book Archive